TheraRadar
Clinical-Stage Companies / Xspray Pharma

Xspray Pharma

Pre-Approval PRO BETA
🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 11/15/2024

6
Total Trials
0
Phase 3
0
Phase 2
0
Recruiting
18
Score

Pipeline by Phase

Phase 3
Phase 2
Phase 1
6

Therapeutic Focus

Cancer Pharmacokinetics Drug-drug Interaction Study Bioavailability Biological Availability

Clinical Trials (6)

NCT07138352 Phase 1 COMPLETED

Bioavailability Study of XS003 (Nilotinib)

Started: 10/3/2024

NCT07138378 Phase 1 COMPLETED

A Bioavailability Study of Nilotinib in Healthy, Adult, Human Subjects Under Fasted Conditions.

Started: 11/15/2024

NCT06145217 Phase 1 COMPLETED

An Drug-drug Interaction Study to Evaluate the Effects of Omeprazole 40mg on the Pharmacokinetics of SPRYCEL®

Started: 8/22/2023

NCT05967377 Phase 1 COMPLETED

Evaluating the Pharmacokinetic Parameters and Relative Bioavailability of Sorafenib (XS005) in Healthy Male Subjects

Started: 11/16/2018

NCT05439408 Phase 1 COMPLETED

Comparative Bioavailability of XS004 (Dasatinib) Formulation G and SPRYCEL® (Dasatinib) in Healthy, Adult Subjects Under Fasting Conditions

Started: 6/7/2021

NCT05433896 Phase 1 COMPLETED

Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions

Started: 11/1/2020

Drug Candidates

XS003 under fed and fasted condition XS003 (nilotinib) Tasigna (nilotinib) SPRYCEL® (dasatinib) 100 mg Film-Coated Tablets in combination with Omeprazole Delayed-Release Capsules USP, 40 mg Sorafenib - Period 1 XS005 Sorafenib Capsule A - Period 1 XS005 Sorafenib Tablet A - Period 1 XS005 Sorafenib Capsule A - Period 2 XS005 Sorafenib Tablet A - Period 2 Sorafenib - Period 2
Activity Status: Slowing
Last Trial Started: 11/15/2024
Last Trial Ended: 1/8/2025
Trials (12 months): 0
Completed Trials: 6
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.